259 related articles for article (PubMed ID: 36702693)
1. Evaluation of safety and immuno-efficacy of a next generation live-attenuated yellow fever vaccine in cynomolgus macaques.
Piras-Douce F; Broudic K; Chautard E; Raynal F; Courtois V; Gautheron S; Mantel N
Vaccine; 2023 Feb; 41(8):1457-1470. PubMed ID: 36702693
[TBL] [Abstract][Full Text] [Related]
2. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
[TBL] [Abstract][Full Text] [Related]
3. Absence of transmission of vYF next generation Yellow Fever vaccine in mosquitoes.
Bellone R; Mousson L; Bohers C; Mantel N; Failloux AB
PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010930. PubMed ID: 36516120
[TBL] [Abstract][Full Text] [Related]
4. Development of a Bicistronic Yellow Fever Live Attenuated Vaccine with Reduced Neurovirulence and Viscerotropism.
Wang HJ; Guo Y; He MJ; Liu ZY; Ye Q; Huang XY; Deng YQ; Li XF; Qin CF
Microbiol Spectr; 2022 Oct; 10(5):e0224622. PubMed ID: 35980184
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model.
Julander JG; Testori M; Cheminay C; Volkmann A
Front Immunol; 2018; 9():1756. PubMed ID: 30116244
[TBL] [Abstract][Full Text] [Related]
6. Cynomolgus macaques as a translational model of human immune responses to yellow fever 17D vaccination.
Mantel N; Piras-Douce F; Chautard E; Marcos-Lopez E; Bodinham CL; Cosma A; Courtois V; Dhooge N; Gautheron S; Kaufmann SHE; Pizzoferro K; Lewis DJM; Martinon F; Pagnon A; Raynal F; Dereuddre-Bosquet N; Le Grand R
J Virol; 2024 May; 98(5):e0151623. PubMed ID: 38567951
[TBL] [Abstract][Full Text] [Related]
7. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
Kum DB; Boudewijns R; Ma J; Mishra N; Schols D; Neyts J; Dallmeier K
Emerg Microbes Infect; 2020; 9(1):520-533. PubMed ID: 32116148
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex.
Davis EH; Beck AS; Strother AE; Thompson JK; Widen SG; Higgs S; Wood TG; Barrett ADT
mBio; 2019 Oct; 10(5):. PubMed ID: 31641088
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic and genetic characterization of a next generation live-attenuated yellow fever vaccine candidate.
Esson R; Rodrigues De Sousa E; Benair L; Devard N; Soulet D; Gillet A; Bassard I; Falque S; Chareyre A; Marmin M; Girerd-Chambaz Y; Logvinoff C; Navarro Sanchez ME
Vaccine; 2022 Sep; 40(38):5641-5650. PubMed ID: 36028455
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever.
Schäfer B; Holzer GW; Joachimsthaler A; Coulibaly S; Schwendinger M; Crowe BA; Kreil TR; Barrett PN; Falkner FG
PLoS One; 2011; 6(9):e24505. PubMed ID: 21931732
[TBL] [Abstract][Full Text] [Related]
11. Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models.
Ma J; Yakass MB; Jansen S; Malengier-Devlies B; Van Looveren D; Sanchez-Felipe L; Vercruysse T; Weynand B; Javarappa MPA; Quaye O; Matthys P; Roskams T; Neyts J; Thibaut HJ; Dallmeier K
EBioMedicine; 2022 Sep; 83():104240. PubMed ID: 36041265
[TBL] [Abstract][Full Text] [Related]
12. Early IFN-gamma production after YF 17D vaccine virus immunization in mice and its association with adaptive immune responses.
Neves PC; Santos JR; Tubarão LN; Bonaldo MC; Galler R
PLoS One; 2013; 8(12):e81953. PubMed ID: 24324734
[TBL] [Abstract][Full Text] [Related]
13. Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection
Douam F; Soto Albrecht YE; Hrebikova G; Sadimin E; Davidson C; Kotenko SV; Ploss A
mBio; 2017 Aug; 8(4):. PubMed ID: 28811340
[TBL] [Abstract][Full Text] [Related]
14. Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE; Marjason J; Bennett S; Aaskov J; Elliott S; McCarthy K; Kanesa-Thasan N; Feroldi E; Reid M
Hum Vaccin; 2010 Nov; 6(11):906-14. PubMed ID: 20864814
[TBL] [Abstract][Full Text] [Related]
15. Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.
Monath TP; Lee CK; Julander JG; Brown A; Beasley DW; Watts DM; Hayman E; Guertin P; Makowiecki J; Crowell J; Levesque P; Bowick GC; Morin M; Fowler E; Trent DW
Vaccine; 2010 May; 28(22):3827-40. PubMed ID: 20347059
[TBL] [Abstract][Full Text] [Related]
16. [Development of inactivated cultural yellow fever vaccine].
Ivanov AP; Klebleeva TD; Rogova YV; Ivanova OE
Vopr Virusol; 2020 Sep; 65(4):212-217. PubMed ID: 33533224
[TBL] [Abstract][Full Text] [Related]
17. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.
Muyanja E; Ssemaganda A; Ngauv P; Cubas R; Perrin H; Srinivasan D; Canderan G; Lawson B; Kopycinski J; Graham AS; Rowe DK; Smith MJ; Isern S; Michael S; Silvestri G; Vanderford TH; Castro E; Pantaleo G; Singer J; Gillmour J; Kiwanuka N; Nanvubya A; Schmidt C; Birungi J; Cox J; Haddad EK; Kaleebu P; Fast P; Sekaly RP; Trautmann L; Gaucher D
J Clin Invest; 2014 Jul; 124(7):3147-58. PubMed ID: 24911151
[TBL] [Abstract][Full Text] [Related]
18. Characterization of "Off-Target" Immune Modulation Induced by Live Attenuated Yellow Fever Vaccine.
Xiang J; Chang Q; McLinden JH; Bhattarai N; Welch JL; Kaufman TM; Stapleton JT
J Infect Dis; 2024 Mar; 229(3):786-794. PubMed ID: 36994927
[TBL] [Abstract][Full Text] [Related]
19. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
[TBL] [Abstract][Full Text] [Related]
20. Isolation of a Potently Neutralizing and Protective Human Monoclonal Antibody Targeting Yellow Fever Virus.
Doyle MP; Genualdi JR; Bailey AL; Kose N; Gainza C; Rodriguez J; Reeder KM; Nelson CA; Jethva PN; Sutton RE; Bombardi RG; Gross ML; Julander JG; Fremont DH; Diamond MS; Crowe JE
mBio; 2022 Jun; 13(3):e0051222. PubMed ID: 35420472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
